ERBB2 and breast cancer: Our pathology analysis of the MICRA study shows that limited but relevant residual invasive disease was missed in patients with TN or HER2-postive breast cancer when surgery was omitted.19 Therefore, it is time to consider alternative de-escalation strategies, such as omission of radiotherapy instead of surgery.